Borosil Scientific Limited has reported its audited financial results for the year ended March 31, 2026. The company posted a consolidated net profit of ₹34.6 crore for FY26, a 29.4% increase from ₹26.7 crore in the previous year. Total consolidated revenue rose 6.6% to ₹467.3 crore from ₹438.5 crore in FY25. The standalone net profit stood at ₹39.7 crore, up 13.4% year-on-year, with revenue from operations reaching ₹42.75 crore.

Financial Performance

For the quarter ended March 31, 2026, the standalone net profit was ₹21.5 crore on revenue of ₹131.9 crore. On a consolidated basis, Q4FY26 net profit surged to ₹27.2 crore from ₹8.6 crore in the corresponding period of the previous year, while revenue grew 10.6% to ₹143.2 crore. The company's board approved the financial statements on May 20, 2026.

Operational Highlights

The financial results included exceptional items amounting to ₹8.53 crore. This comprised an expenditure of ₹6.61 crore related to a Voluntary Retirement Scheme (VRS) at the Ambad, Nashik plant and a one-time provision of ₹1.92 crore due to newly introduced Labour Codes. The company noted that despite one-time expenses related to discontinued operations at the Ambad plant, Standalone EBITDA grew during the year. Consolidated PAT was further supported by the recognition of Deferred Tax Assets in Goel Scientific Glass Works Limited.

Segment Performance

The Scientific segment led growth, with consolidated sales for FY26 reaching ₹330.9 crore, a 6.8% increase. The Glassware segment recorded sales of ₹130.8 crore. For Q4FY26, consolidated sales in the Scientific segment stood at ₹109.6 crore, while the Glassware segment contributed ₹31.8 crore. The company attributed the Q4 EBITDA improvement to higher sales and enhanced production efficiency, alongside a one-time income from the reversal of provisions at Goel Scientific Glass Works Limited.

Borosil Scientific Limited’s Nomination and Remuneration Committee (NRC) has approved the grant of 18,700 stock options under its Employee Stock Option Scheme. The decision was taken during a meeting held on May 20, 2026. Each stock option entitles the holder to apply for one equity share of the company with a face value of Re. 1.

The options have been granted at a price of Rs. 108 per share. This pricing represents approximately a 10% discount on the market price, which was determined based on the closing price on the National Stock Exchange of India Limited (NSE) on May 19, 2026. The NSE was selected as the reference exchange as it recorded the highest trading volume in the company's shares on the preceding trading day.

The vesting schedule for these options is structured over a four-year period. The options will vest in equal annual installments of 25% each, starting from the first anniversary of the grant date. The exercise period for the options is set at five years from the date of vesting for the respective tranches.

Key Details of the Grant

The following table outlines the specific details regarding the grant of stock options:

Vesting Schedule

The options granted will vest according to the following timeline:

The company confirmed that the scheme is in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. As of the date of the intimation, no options have been vested, exercised, or lapsed, and no money has been realized from the exercise of options.